Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced the interim clinical results from its ongoing Phase 1/2 first-in-human trial ...
Renee Long, from the University of California San Diego, took some time to discuss her poster on the viability of Grok as a ...
According to Aldeyra Therapeutics, a phase 2/3 trial of ADX-2191 in patients with retinitis pigmentosa is expected to begin in 2025. The Food and Drug Administration (FDA) has granted Fast Track ...
Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision ...
A Dartmouth woman's fundraising efforts to undergo a costly eye surgery in Cuba has experts warning about the dangers of travelling abroad for medical care. Adrienne LeClair-Hamm, who lost part of her ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
The FDA has granted Orphan Drug designation to ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa. The Food and Drug Administration (FDA) has granted Orphan ...
Researchers at the National Eye Institute have found that the complement system seems to protect against retinal degeneration in retinitis pigmentosa. The research contradicts previous findings, which ...
STOCKHOLM — Trial results are demonstrating the safety and effectiveness of a novel gene modifier therapy for treating retinitis pigmentosa associated with NR2E3 and RHO mutations. Researchers ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted fast track designation to MCO-010 from Nanoscope Therapeutics for the treatment of retinitis ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted rare pediatric disease designation to VG901 for retinitis pigmentosa. An independent data safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results